您好,欢迎光临欣博盛生物科技商城!
服务热线:400 680 0892
新闻资讯 News

BioXCell热销产品--RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A)

2023-10-15
浏览次数: 40

BioXCell热销产品--RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A)

 

产品描述:

10F.9G2™-CP001单克隆抗体是原始10F.9G2™单克隆抗体的重组嵌合型抗体。可变结构域序列与原始10F.9G2™克隆号相同,但是恒定区序列已经从大鼠IgG2b变为小鼠IgG1。10F.9G2™-CP001单克隆抗体在Fc片段中也含有D265A突变,使其无法与内源性Fcγ受体结合。

 

10F.9G2™-CP001单克隆抗体与小鼠PD-L1(程序性死亡配体1,也称为B7-H1或CD274)反应。PD-L1是属于Ig超家族的B7家族的I型跨膜蛋白,分子量为40kDa。PD-L1在T淋巴细胞、B淋巴细胞、NK细胞、树突状细胞以及IFNγ刺激的单核细胞、上皮细胞和内皮细胞上表达。PD-L1与CD4和CD8胸腺细胞以及活化的T和B淋巴细胞和骨髓细胞上的受体PD-1结合。PD-L1与PD-1的结合导致抑制TCR介导的T细胞增殖和细胞因子产生。PD-L1被认为在肿瘤免疫逃逸中起着重要作用。诱导的PD-L1表达在许多肿瘤中很常见,并导致肿瘤细胞对CD8+ T细胞介导的裂解的抗性增加。在黑色素瘤的小鼠模型中,可以通过用阻断PD-L1和PD-1之间相互作用的抗体进行治疗,暂时抑制肿瘤生长。10F.9G2™单克隆抗体已被证明可以阻断PD-L1和PD-1之间以及PD-L1和B7-1之间的相互作用(CD80)。

 

产品详情:

产品名称

RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A)

产品货号

CP001

产品规格

1mg

反应种属

Mouse

克隆号

10F.9G2™-CP001

同种型

Mouse IgG1(switched from rat IgG2b)

免疫原

Mouse CD274

实验应用

in vivo PD-L1 blockade*

Immunofluorescence*

Immunohistochemistry (frozen)*

Flow cytometry*

Western blot*

*Reported for the original rat IgG2b 10F.9G2 antibody

产品形式

PBS, pH 7.0,Contains no stabilizers or preservatives

纯度

>95%, Determined by SDS-PAGE

聚合

<5%, Determined by SEC

无菌处理

0.2 µm filtration

纯化方式

Protein A

分子量

150 kDa

小鼠病原检测

Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

保存条件

抗体原液保存在4°C,不能冷冻保存。

推荐抗体稀释液

InVivoPure pH 7.0 Dilution Buffer(货号IP0070)

 

该产品自上市已被多篇SCI文献引用,品质有保证,以下是部分已发表的文献引用:

应用

文章

体内PD-L1阻断

(in vivo PD-L1 blockade)

1. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic 

Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front 

Immunol 9: 2100.


2. Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl 

Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory 

T Cells' Immunity 49(2): 247-263 e247.


3. Jaworska, K., et al. (2015). 'Both PD-1 ligands protect the kidney from ischemia 

reperfusion injury' J Immunol 194(1): 325-333.


4. Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is 

intrinsic and is not determined by CD4 help' Nat Commun 6: 7994.


5. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk 

Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell 

Host Microbe 17(5): 628-641.

体内PD-L1阻断,流式细胞术

(in vivo PD-L1 blockade, Flow 

Cytometry)

1. Aloulou, M., et al. (2016). 'Follicular regulatory T cells can be specific for the 

immunizing antigen and derive from naive T cells' Nat Commun 7: 10579.


2. Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 

Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811.


3. Rutigliano, J. A., et al. (2014). 'Highly pathological influenza A virus infection is 

associated with augmented expression of PD-1 by functionally compromised 

virus-specific CD8+ T cells' J Virol 88(3): 1636-1651.

体内PD-L1阻断,免疫荧光

(in vivo PD-L1 blockade, 

Immunofluorescence)

1.Willimsky, G., et al. (2013). 'Virus-induced hepatocellular carcinomas cause 

antigen-specific local tolerance' J Clin Invest 123(3): 1032-1043.

免疫组织化学(冷冻),免疫荧光

(Immunohistochemistry (frozen), 

Immunofluorescence)

1.Riella, L. V., et al. (2011). 'Essential role of PDL1 expression on nonhematopoietic 

donor cells in acquired tolerance to vascularized cardiac allografts' Am J Transplant 

11(4): 832-840.

 

 

 

 

六码一抗 不分包装 全面EXTRA 5% OFF

更多产品详情请咨询 BioXCell 中国授权代理——欣博盛生物

全国服务热线: 4006-800-892       邮箱: market@neobioscience.com 

深圳: 0755-26755892         北京: 010-88594029            

广州:020-87615159           上海: 021-34613729

代理品牌网站: www.neobioscience.com 

自主品牌网站: www.neobioscience.net 

分享到:
关注欣博盛公众号
Copyright ©2021 - 2023 深圳欣博盛生物科技有限公司
  网站地图
犀牛云提供企业云服务